Posted by Michael Wonder on 14 Oct 2021
Celltrion applies for product approval for Avastin biosimilar in EU
12 October 2021 - Celltrion said that it has completed the approval application procedure for CT-P16, a biosimilar of Avastin (bevacizumab), to the EMA.
"We submitted the application after completing global clinical trials for a total of 689 patients at 164 sites in 21 countries since 2018," the company said. "We plan to obtain for all indications covered by Avastin, including metastatic colorectal cancer and non-small cell lung cancer."
